See more : DeTai New Energy Group Limited (0559.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Pyxis Oncology, Inc. (PYXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pyxis Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- TIME dotCom Berhad (5031.KL) Income Statement Analysis – Financial Results
- MRT Inc. (6034.T) Income Statement Analysis – Financial Results
- Taiwan Navigation Co., Ltd. (2617.TW) Income Statement Analysis – Financial Results
- Ashford Hospitality Trust, Inc. (AHT) Income Statement Analysis – Financial Results
- Radaan Mediaworks India Limited (RADAAN.BO) Income Statement Analysis – Financial Results
Pyxis Oncology, Inc. (PYXS)
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.00M | 1.84M | 1.25M | 444.00K | 0.00 |
| Gross Profit | -2.00M | -1.84M | -1.25M | -444.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 49.59M | 86.13M | 51.05M | 9.05M | 1.22M |
| General & Administrative | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.61M | 37.35M | 18.66M | 3.85M | 1.66M |
| Other Expenses | 0.00 | 0.00 | 181.00K | 0.00 | 0.00 |
| Operating Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Cost & Expenses | 82.20M | 123.48M | 69.72M | 12.89M | 2.88M |
| Interest Income | 6.63M | 2.76M | 23.00K | 66.00K | 107.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.00M | 1.84M | 1.25M | 444.00K | 2.88M |
| EBITDA | -78.49M | -122.77M | -69.07M | -12.43M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -82.20M | -123.48M | -69.72M | -12.89M | -2.88M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.41M | 2.76M | -6.26M | 66.00K | 107.00K |
| Income Before Tax | -73.79M | -120.72M | -75.98M | -12.83M | -2.77M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.76M | 5.56M | -66.00K | -107.00K |
| Net Income | -73.79M | -117.95M | -81.54M | -12.76M | -2.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| EPS Diluted | -1.85 | -3.57 | -2.53 | -0.37 | -0.08 |
| Weighted Avg Shares Out | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
| Weighted Avg Shares Out (Dil) | 39.90M | 33.03M | 32.22M | 34.31M | 34.31M |
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
Pyxis Oncology Successfully Completes Acquisition of Apexigen
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan
Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors
Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates
Source: https://incomestatements.info
Category: Stock Reports